NCT00687193

Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 318 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the dose-response relationship of 5 dose of CP-690,550, compared to placebo for the treatment of signs and symptoms in patients with active RA who failed an adequate trial of therapy with at least 1 DMARD in a 12-week therapy.

Conditions

• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	Placebo	Placebo BID, 3 blinded tablets administered BID for 12 weeks
DRUG	CP-690,550	10mg BID, 3 blinded tablets administered BID for 12 weeks
DRUG	CP-690,550	15mg BID, 3 blinded tablets administered BID for 12 weeks
DRUG	CP-690,550	1mg BID, 3 blinded tablets administered BID for 12 weeks
DRUG	CP-690,550	3mg BID, 3 blinded tablets administered BID for 12 weeks
DRUG	CP-690,550	5mg BID, 3 blinded tablets administered BID for 12 weeks

Timeline

• Start date: 2009-03-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2008-05-30
• Last updated: 2013-03-25
• Results posted: 2012-12-25

Locations

40 sites across 1 country: Japan